ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2175

Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome   

Maria Ester Simeira Fonseca1, Michelle Lopes2, Christiane Pereira Gouvea3 and Danieli Andrade4, 1Rheumatology, University of São Paulo, São Paulo, Brazil, 2Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 3Hematology, University of São Paulo, São Paulo, Brazil, 4Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Anticoagulation, antiphospholipid syndrome, management and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Antiphospholipid Syndrome: Basic Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it can occur in patients with no autoimmune disease. The standard treatment for thrombotic APS is anticoagulation with vitamin K antagonists. The prothrombin time (PT) and its corresponding INR (International English Normatized ratio) is the laboratory test used to target anticoagulation. Because inadequate anticoagulation therapy may be hazardous, a strict monitoring is needed. The CoaguCheck XS is a simple and prompt device that allows INR monitoring providing the result in seconds. Despite studies comparing CoaguCheck XS and PT analysis presented favorable correlation, there are scarce studies evaluating the use of CoaguCheck in APS patients. Purpose: Evaluate accuracy of CoaguCheck XS in APS patients, comparing it with standard method for plasma prothrombin time (PT). Furthermore, we analyzed other clinical and laboratorial features to check if they could interfere with CoaguCheck results. 

Methods: This is a single center cross-sectional study with 94 APS patients from a rheumatology clinic tertiary hospital included from august 2014 to march 2015. All patients fulfilled APS Sydney´s criteria and all APS associated with SLE fulfilled ACR SLE criteria. The comparison of Coagucheck XS results versus standard laboratory practice for monitoring anticoagulant therapy was evaluated using the coefficient of determination (r) followed by the Bland-Altman test. Paired T test was also applied.

 Results:  The comparison between INR values from 94 patients measured with CoaguCheck XS and the standard PT resulted in a coefficient of correlation (r) of 0.95. The mean INR (S.D.) was 2.94 (1.41) with CoaguCheck XS and 2.43 (0.86) with standard PT. Dividing the INR values in into four ranges (INR < 2, INR 2-3, INR 3-4 and INR>4) we found that INR>4 group presented a poor correlation (r=0.64) compared to the other ranges (p<0.05). Although CoaguChek XS and standard PT are highly correlated, the INR values were not equal. In general CoacuCheck shows higher values than the standard PT test, with an average of 0.42 ± 0.54. Therefore we propose a simple linear regression model in order to predict the PT standard values using values obtained from CoaguChek. The model showed a R2 of 87%, indicating a good quality of forecast, for INR<2.5. None of the clinical or laboratory variables evaluated interfered with CoaguCheck results. There was no difference in testing performance in primary APS and APS associated with SLE patients. 

Conclusion: CoaguCheck XS is a simple and acceptable way of monitoring anticoagulation in APS patients presenting a good correlation with standard PT test if INR is <4. These results corfim previous reports from anticoagulated patients with no antiphospholipid syndrome.


Disclosure: M. E. Simeira Fonseca, None; M. Lopes, None; C. Pereira Gouvea, None; D. Andrade, None.

To cite this abstract in AMA style:

Simeira Fonseca ME, Lopes M, Pereira Gouvea C, Andrade D. Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome    [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/comparative-study-between-coagucheck-xs-versus-standard-laboratory-practice-protrombine-time-for-monitoring-anticoagulant-therapy-in-patients-with-antiphos/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-study-between-coagucheck-xs-versus-standard-laboratory-practice-protrombine-time-for-monitoring-anticoagulant-therapy-in-patients-with-antiphos/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology